If you are a non-UPMC provider and would like to order the Monoclonal Antibody Infusion for a patient under your care, and unable to place orders in UPMC’s electronic medical record, please:
Your patients can learn more and see if they qualify for treatment by calling 866-804-5251.
UPMC is one of the few health care organizations in Pennsylvania offering monoclonal antibody treatment, which is authorized by the FDA for emergency use in the treatment of COVID-19.
This one-time infusion may help keep certain individuals with mild to moderate COVID-19 from progressing in their illness to severe disease and may make it less likely that a patient would need to go to the emergency department or need hospitalization.
UPMC is using two monoclonal antibody infusion treatment products in outpatient infusion center locations throughout western, central, and north central PA. These include:
Casirivimab & Imdevimab, manufacturer – Regeneron
Casirivimab and Imdevimab EUA Fact Sheet for Providers
Bamlanivimab & Etesevimab, Manufacturer – Eli Lilly
Bamlanivimab & Etesevimab Fact Sheet for Providers
UPMC can administer available monoclonal antibody treatments for COVID-19 positive patients who meet specific criteria and for whom the antibodies may be an effective treatment.
Confirmed COVID-19 positive patients AND mild symptoms* for ≤ 9 days AND one of the following criteria:
*Symptoms include: Fever, cough, sore throat, malaise, headache, muscle pain, GI symptoms, or shortness of breath with exertion.
Not authorized for use in patients:
Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.
There is limited experience treating pregnant women or breastfeeding mothers with bamlanivimab. For a mother and unborn baby, the benefit of receiving bamlanivimab may be greater than the risk from the treatment. If your patient is pregnant or breastfeeding, discuss options and specific situation with the patient and health care provider.
With many infusions, there is a risk of allergic reaction to the infusion, albeit reactions to these medications requiring discontinuation are very rare. The infusion centers have trained staff and appropriate medications to address any reaction, including: fever, chills, nausea, headache, shortness of breath, low blood pressure, wheezing, swelling of lips, face, or throat, rash including hives, itching, muscle aches, and dizziness.
Per the CDC, COVID-19 vaccination should be deferred for at least 90 days after receiving monoclonal antibody infusion.
Persons who have received a COVID-19 vaccine may receive monoclonal antibody at any point after vaccination, if the patient is a candidate based on COVID-19 disease.
Check out our web page for information for patients about monoclonal antibody treatment.